PriceTargets.com logo

Vertex Pharmaceuticals - VRTX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $499.12
  • Forecasted Upside: 10.61%
  • Number of Analysts: 30
  • Breakdown:
  • 3 Sell Ratings
  • 9 Hold Ratings
  • 17 Buy Ratings
  • 1 Strong Buy Ratings
$451.23 As of 11/20/2024 01:00 AM ET
▲ +3.22 (0.72%)

This chart shows the closing price for VRTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vertex Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VRTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VRTX

Analyst Price Target is $499.12
▲ +10.61% Upside Potential
This price target is based on 30 analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is $499.12, with a high forecast of $600.00 and a low forecast of $325.00. The average price target represents a 10.61% upside from the last price of $451.23.

This chart shows the closing price for VRTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 30 contributing investment analysts is to moderate buy stock in Vertex Pharmaceuticals. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 11 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 7 hold ratings
  • 3 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 15 buy ratings
  • 7 hold ratings
  • 3 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 16 buy ratings
  • 7 hold ratings
  • 3 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 17 buy ratings
  • 9 hold ratings
  • 3 sell ratings
Ratings as of
10/21/2024
  • 1 strong buy ratings
  • 17 buy ratings
  • 9 hold ratings
  • 3 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 17 buy ratings
  • 9 hold ratings
  • 3 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/14/2024CitigroupInitiated CoverageBuy$575.00
11/13/2024CitigroupUpgradeStrong-Buy
11/6/2024Canaccord Genuity GroupBoost TargetSell ➝ Sell$361.00 ➝ $408.00
11/5/2024ScotiabankBoost TargetSector Perform ➝ Sector Perform$480.00 ➝ $486.00
11/5/2024UBS GroupBoost TargetBuy ➝ Buy$562.00 ➝ $586.00
11/5/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$437.00 ➝ $451.00
11/5/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$480.00 ➝ $480.00
11/5/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$510.00 ➝ $503.00
11/5/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$473.00 ➝ $476.00
10/30/2024OppenheimerLower TargetOutperform ➝ Outperform$550.00 ➝ $540.00
10/21/2024HC WainwrightReiterated RatingBuy ➝ Buy$600.00 ➝ $600.00
10/17/2024UBS GroupBoost TargetBuy ➝ Buy$477.00 ➝ $562.00
10/16/2024ScotiabankInitiated CoverageSector Perform$480.00
10/14/2024Bank of AmericaLower TargetBuy ➝ Buy$550.00 ➝ $541.00
10/10/2024Raymond JamesReiterated RatingMarket Perform
10/8/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$480.00 ➝ $480.00
10/4/2024Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$431.00 ➝ $425.00
10/1/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$462.00 ➝ $474.00
9/19/2024Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$431.00 ➝ $431.00
8/5/2024HC WainwrightBoost TargetBuy ➝ Buy$500.00 ➝ $600.00
8/5/2024OppenheimerBoost TargetOutperform ➝ Outperform$500.00 ➝ $550.00
8/5/2024Truist FinancialReiterated RatingBuy ➝ Buy$508.00 ➝ $550.00
8/5/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$505.00 ➝ $510.00
8/5/2024BarclaysDowngradeOverweight ➝ Equal Weight$472.00 ➝ $509.00
8/2/2024GuggenheimBoost TargetBuy ➝ Buy$450.00 ➝ $558.00
8/2/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$480.00 ➝ $480.00
8/2/2024Piper SandlerBoost TargetOverweight ➝ Overweight$500.00 ➝ $535.00
7/31/2024Canaccord Genuity GroupBoost TargetSell ➝ Sell$371.00 ➝ $376.00
7/26/2024Needham & Company LLCReiterated RatingHold
7/23/2024TD CowenBoost TargetBuy ➝ Buy$450.00 ➝ $500.00
7/22/2024Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$440.00 ➝ $480.00
7/19/2024HC WainwrightBoost TargetBuy ➝ Buy$462.00 ➝ $500.00
7/11/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$402.00 ➝ $455.00
6/27/2024Redburn AtlanticInitiated CoverageBuy$545.00
6/24/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$540.00 ➝ $555.00
6/17/2024ArgusBoost TargetBuy ➝ Buy$465.00 ➝ $550.00
6/11/2024Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$424.00 ➝ $421.00
6/4/2024Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$424.00 ➝ $424.00
5/31/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$480.00 ➝ $500.00
5/7/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$417.00 ➝ $424.00
5/7/2024Piper SandlerBoost TargetOverweight ➝ Overweight$450.00 ➝ $456.00
5/7/2024Needham & Company LLCReiterated RatingHold
5/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$462.00
4/18/2024GuggenheimBoost TargetBuy ➝ Buy$445.00 ➝ $450.00
4/17/2024UBS GroupLower TargetBuy ➝ Buy$498.00 ➝ $466.00
4/15/2024OppenheimerReiterated RatingOutperform ➝ Outperform$500.00
4/12/2024Canaccord Genuity GroupReiterated RatingSell ➝ Sell$371.00
4/11/2024Evercore ISIUpgradeIn-Line ➝ Outperform$438.00
4/11/2024HC WainwrightBoost TargetBuy ➝ Buy$457.00 ➝ $462.00
2/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$440.00
2/15/2024Wolfe ResearchInitiated CoverageOutperform$515.00
2/6/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$440.00
2/6/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$397.00 ➝ $420.00
2/6/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$500.00 ➝ $540.00
2/6/2024BarclaysBoost TargetOverweight ➝ Overweight$446.00 ➝ $472.00
2/6/2024William BlairReiterated RatingOutperform
2/6/2024Evercore ISIDowngradeOutperform ➝ In-Line$436.00 ➝ $438.00
2/6/2024HC WainwrightBoost TargetBuy ➝ Buy$397.00 ➝ $457.00
2/2/2024Sanford C. BernsteinDowngradeOutperform ➝ Market Perform
2/1/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$390.00 ➝ $438.00
1/31/2024Truist FinancialBoost TargetBuy ➝ Buy$456.00 ➝ $508.00
1/31/2024Robert W. BairdDowngradeNeutral ➝ Underperform$325.00
1/31/2024Maxim GroupDowngradeBuy ➝ Hold
1/24/2024Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$415.00 ➝ $440.00
1/24/2024Canaccord Genuity GroupReiterated RatingHold ➝ Sell$332.00 ➝ $379.00
1/24/2024Canaccord Genuity GroupDowngradeHold ➝ Sell$332.00 ➝ $379.00
1/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$415.00
12/14/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$380.00
12/14/2023Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$347.00 ➝ $379.00
12/11/2023BarclaysBoost TargetOverweight ➝ Overweight$408.00 ➝ $415.00
12/11/2023HC WainwrightBoost TargetBuy ➝ Buy$390.00 ➝ $397.00
12/5/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$380.00
11/22/2023Stifel NicolausReiterated RatingHold ➝ Hold$373.00
11/16/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$380.00
11/8/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$359.00 ➝ $364.00
11/7/2023Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$350.00 ➝ $347.00
11/7/2023BMO Capital MarketsBoost TargetOutperform ➝ Outperform$389.00 ➝ $415.00
11/7/2023Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$370.00 ➝ $380.00
11/7/2023Stifel NicolausBoost TargetHold ➝ Hold$340.00 ➝ $373.00
11/7/2023HC WainwrightBoost TargetBuy ➝ Buy$380.00 ➝ $390.00
10/16/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$370.00
10/9/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$352.00 ➝ $359.00
10/4/2023Truist FinancialReiterated RatingBuy ➝ Buy$456.00
9/29/2023Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$343.00 ➝ $348.00
9/7/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$370.00
8/7/2023Canaccord Genuity GroupBoost TargetHold ➝ Hold$312.00 ➝ $315.00
8/2/2023HC WainwrightReiterated RatingBuy ➝ Buy$380.00
8/2/2023OppenheimerReiterated RatingOutperform ➝ Outperform$410.00
8/2/2023BMO Capital MarketsBoost TargetOutperform ➝ Outperform$385.00 ➝ $389.00
8/2/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$340.00 ➝ $352.00
8/2/2023Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$325.00 ➝ $343.00
8/2/2023Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$410.00 ➝ $425.00
8/2/2023Sanford C. BernsteinBoost TargetOutperform ➝ Outperform$380.00 ➝ $390.00
8/2/2023BarclaysBoost TargetOverweight ➝ Overweight$384.00 ➝ $399.00
7/21/2023Bank of AmericaBoost TargetBuy$350.00 ➝ $400.00
7/3/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$305.00 ➝ $340.00
6/26/2023888Reiterated RatingReiterates
6/26/2023Evercore ISIBoost Target$375.00 ➝ $379.00
6/8/2023Royal Bank of CanadaBoost Target$315.00 ➝ $323.00
5/30/2023William BlairInitiated CoverageOutperform$382.00
5/25/2023Westpark CapitalInitiated CoverageHold
5/3/2023Maxim GroupBoost Target$325.00 ➝ $400.00
5/3/2023Sanford C. BernsteinBoost Target$344.00 ➝ $363.00
5/2/2023Royal Bank of CanadaBoost Target$299.00 ➝ $315.00
5/2/2023Truist FinancialBoost Target$341.00 ➝ $456.00
5/2/2023Stifel NicolausBoost Target$300.00 ➝ $340.00
5/2/2023GuggenheimBoost Target$339.00 ➝ $385.00
5/2/2023Robert W. BairdBoost Target$280.00 ➝ $325.00
5/2/2023OppenheimerBoost Target$350.00 ➝ $410.00
5/2/2023HC WainwrightBoost Target$326.00 ➝ $380.00
5/2/2023BarclaysBoost Target$342.00 ➝ $384.00
3/29/2023ArgusBoost TargetBuy$340.00 ➝ $350.00
3/21/2023Sanford C. BernsteinInitiated CoverageOutperform$344.00
2/8/2023Morgan StanleyLower TargetEqual Weight$286.00 ➝ $285.00
2/8/2023Piper SandlerReiterated RatingNeutral$296.00
2/8/2023SVB SecuritiesLower Target$374.00 ➝ $365.00
2/8/2023Leerink PartnersLower TargetOutperform$374.00 ➝ $365.00
2/8/2023HC WainwrightBoost TargetBuy$300.00 ➝ $325.00
2/8/2023BarclaysBoost TargetOverweight$313.00 ➝ $342.00
1/24/2023Morgan StanleyBoost TargetEqual Weight$285.00 ➝ $286.00
1/19/2023Piper SandlerBoost TargetNeutral$293.00 ➝ $296.00
1/18/2023Canaccord Genuity GroupInitiated CoverageHold$311.00
1/17/2023Leerink PartnersUpgradeMarket Perform ➝ Outperform$374.00
12/19/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$340.00
11/17/2022ArgusBoost TargetBuy$320.00 ➝ $340.00
11/1/2022GuggenheimBoost Target$318.00
11/1/2022Robert W. BairdBoost Target$280.00
10/28/2022Royal Bank of CanadaBoost TargetSector Perform$281.00 ➝ $288.00
10/28/2022BarclaysBoost TargetOverweight$307.00 ➝ $313.00
10/28/2022Morgan StanleyBoost TargetEqual Weight$253.00 ➝ $285.00
10/28/2022Wells Fargo & CompanyBoost TargetOverweight$305.00 ➝ $335.00
10/28/2022CowenBoost Target$315.00 ➝ $330.00
10/28/2022CowenBoost Target$315.00 ➝ $330.00
10/24/2022JPMorgan Chase & Co.Boost TargetOverweight$319.00 ➝ $327.00
10/16/2022Piper SandlerBoost Target$288.00 ➝ $293.00
8/16/2022Piper SandlerBoost TargetNeutral$256.00 ➝ $288.00
8/8/2022Morgan StanleyBoost TargetEqual Weight$250.00 ➝ $253.00
8/5/2022HC WainwrightBoost TargetBuy$275.00 ➝ $300.00
8/5/2022BarclaysBoost TargetOverweight$291.00 ➝ $307.00
7/26/2022Piper SandlerBoost TargetNeutral$242.00 ➝ $256.00
7/12/2022Cantor FitzgeraldInitiated CoverageOverweight$365.00
6/13/2022CowenBoost TargetOutperform$305.00 ➝ $310.00
6/13/2022ArgusBoost TargetBuy$275.00 ➝ $280.00
6/13/2022CowenBoost Target$305.00 ➝ $310.00
6/1/2022Maxim GroupUpgradeHold ➝ Buy$325.00
5/23/2022Leerink PartnersInitiated CoverageMarket Perform$265.00
5/6/2022Wells Fargo & CompanyBoost Target$300.00 ➝ $305.00
5/6/2022Robert W. BairdDowngradeOutperform ➝ Neutral$250.00
5/6/2022Piper SandlerLower Target$249.00 ➝ $242.00
5/3/2022Morgan StanleyUpgradeUnderweight ➝ Equal Weight$250.00
4/21/2022Piper SandlerBoost TargetNeutral$245.00 ➝ $249.00
4/13/2022UBS GroupBoost Target$258.00 ➝ $325.00
4/5/2022Wells Fargo & CompanyBoost TargetOverweight$270.00 ➝ $300.00
4/4/2022OppenheimerBoost Target$305.00 ➝ $350.00
3/23/2022HC WainwrightReiterated RatingBuy$275.00
2/3/2022Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$269.00
1/27/2022Wolfe ResearchBoost TargetOutperform$271.00 ➝ $282.00
1/27/2022JPMorgan Chase & Co.Boost TargetOverweight$260.00 ➝ $288.00
1/27/2022Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$268.00 ➝ $269.00
1/27/2022Stifel NicolausBoost TargetHold$213.00 ➝ $222.00
1/27/2022Morgan StanleyBoost TargetUnderweight$203.00 ➝ $208.00
1/20/2022BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$202.00 ➝ $274.00
12/23/2021Evercore ISIReiterated RatingBuy$265.00
12/8/2021Wells Fargo & CompanyInitiated CoverageOverweight$270.00
12/2/2021Royal Bank of CanadaBoost TargetFair Value ➝ Outperform$250.00 ➝ $265.00
11/18/2021BMO Capital MarketsInitiated CoverageMarket Perform$202.00
11/18/2021Piper SandlerDowngradeOverweight ➝ Neutral$323.00 ➝ $218.00
11/3/2021Royal Bank of CanadaBoost TargetOutperform$246.00 ➝ $250.00
9/9/2021Stifel NicolausDowngradeBuy ➝ Hold$244.00 ➝ $213.00
9/7/2021Morgan StanleyDowngradeEqual Weight ➝ Underweight$202.00
7/30/2021Morgan StanleyLower TargetEqual Weight$205.00 ➝ $202.00
7/30/2021Royal Bank of CanadaBoost TargetOutperform$246.00 ➝ $248.00
7/30/2021Leerink PartnersBoost TargetUnderperform$170.00 ➝ $175.00
7/30/2021Piper SandlerBoost TargetOverweight$261.00 ➝ $323.00
7/20/2021Leerink PartnersDowngradeMarket Perform ➝ Underperform$200.00 ➝ $170.00
7/19/2021Wolfe ResearchInitiated CoverageOutperform$252.00
6/30/2021Raymond JamesInitiated CoverageMarket Perform
6/14/2021Truist FinancialBoost TargetBuy$305.00 ➝ $331.00
6/14/2021Piper SandlerLower TargetOverweight$347.00 ➝ $261.00
6/14/2021Leerink PartnersLower TargetReduce ➝ Market Perform$250.00 ➝ $200.00
6/13/2021Evercore ISIReiterated RatingBuy
6/11/2021Stifel NicolausLower TargetBuy$277.00 ➝ $244.00
6/11/2021The Goldman Sachs GroupLower TargetBuy$358.00 ➝ $307.00
6/11/2021BarclaysLower TargetOverweight$302.00 ➝ $285.00
6/11/2021Cantor FitzgeraldLower TargetOverweight$285.00 ➝ $281.00
6/11/2021Morgan StanleyLower TargetEqual Weight$254.00 ➝ $205.00
6/11/2021Robert W. BairdLower TargetOutperform$252.00 ➝ $240.00
6/11/2021Royal Bank of CanadaLower TargetPositive ➝ Outperform$262.00 ➝ $242.00
6/11/2021Daiwa Capital MarketsDowngradeOutperform ➝ Neutral$210.00
5/3/2021Morgan StanleyBoost TargetEqual Weight$253.00 ➝ $254.00
4/26/2021Morgan StanleyBoost TargetEqual Weight$253.00 ➝ $254.00
4/19/2021Morgan StanleyBoost TargetEqual Weight$251.00 ➝ $253.00
4/11/2021Royal Bank of CanadaReiterated RatingBuy
2/23/2021Robert W. BairdUpgradeNeutral ➝ Outperform$220.00 ➝ $252.00
2/2/2021BMO Capital MarketsLower TargetOutperform$302.00 ➝ $284.00
2/2/2021Credit Suisse GroupLower TargetOutperform$285.00 ➝ $280.00
2/2/2021Leerink PartnersLower TargetMarket Perform$257.00 ➝ $250.00
2/2/2021Piper SandlerBoost TargetOverweight$307.00 ➝ $347.00
2/2/2021HC WainwrightLower TargetBuy$315.00 ➝ $275.00
1/19/2021Morgan StanleyBoost TargetEqual Weight$249.00 ➝ $251.00
12/30/2020Daiwa Capital MarketsInitiated CoverageOutperform$250.00
12/11/2020JPMorgan Chase & Co.Reiterated RatingBuy
11/30/2020Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$247.00 ➝ $267.00
11/20/2020Sanford C. BernsteinInitiated CoverageOutperform$275.00
11/1/2020JPMorgan Chase & Co.Reiterated RatingBuy
10/30/2020Piper SandlerLower TargetOverweight$327.00 ➝ $307.00
10/30/2020Credit Suisse GroupLower TargetOutperform$292.00 ➝ $285.00
10/30/2020Leerink PartnersLower TargetMarket Perform$267.00 ➝ $257.00
10/28/2020UBS GroupInitiated CoverageBuy$287.00
10/26/2020Needham & Company LLCReiterated RatingHold
10/19/2020Morgan StanleyLower TargetEqual Weight$281.00 ➝ $249.00
10/15/2020Truist FinancialLower Target$330.00 ➝ $305.00
10/15/2020Leerink PartnersLower TargetMarket Perform$283.00 ➝ $267.00
10/13/2020Morgan StanleyLower TargetEqual Weight$300.00 ➝ $281.00
9/18/2020Maxim GroupReiterated RatingHold
8/24/2020Leerink PartnersBoost TargetNeutral ➝ Market Perform$274.00 ➝ $283.00
7/31/2020Cantor FitzgeraldBoost TargetOverweight$293.00 ➝ $305.00
7/31/2020Leerink PartnersBoost TargetMarket Perform$263.00 ➝ $274.00
7/31/2020HC WainwrightReiterated RatingBuy$295.00 ➝ $315.00
7/31/2020Piper SandlerBoost TargetOverweight$302.00 ➝ $327.00
7/20/2020Credit Suisse GroupBoost TargetOutperform$298.00 ➝ $328.00
7/16/2020CowenBoost TargetOutperform$265.00 ➝ $300.00
7/14/2020Jefferies Financial GroupBoost TargetBuy$295.00 ➝ $340.00
7/8/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$277.00 ➝ $300.00
7/2/2020The Goldman Sachs GroupBoost TargetPositive ➝ Conviction-Buy$290.00 ➝ $330.00
6/24/2020SunTrust BanksBoost TargetBuy$285.00 ➝ $330.00
6/12/2020CitigroupBoost TargetTop Pick ➝ Buy$305.00 ➝ $325.00
5/15/2020ArgusBoost TargetBuy$270.00 ➝ $320.00
5/1/2020CitigroupBoost TargetBuy$265.00 ➝ $305.00
4/30/2020Credit Suisse GroupReiterated RatingBuy$298.00
4/30/2020CfraBoost TargetBuy$286.00 ➝ $297.00
4/30/2020GuggenheimBoost TargetBuy$266.00 ➝ $290.00
4/30/2020BMO Capital MarketsBoost TargetOutperform$279.00 ➝ $283.00
4/30/2020Stifel NicolausBoost TargetBuy$275.00 ➝ $285.00
4/30/2020OppenheimerBoost TargetOutperform$265.00 ➝ $305.00
4/30/2020Morgan StanleyBoost TargetOverweight$258.00 ➝ $277.00
4/30/2020Leerink PartnersBoost TargetMarket Perform$224.00 ➝ $263.00
4/30/2020JMP SecuritiesBoost TargetMarket Outperform$255.00 ➝ $285.00
4/30/2020HC WainwrightBoost TargetBuy$270.00 ➝ $295.00
4/28/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$250.00 ➝ $260.00
4/27/2020Piper SandlerReiterated RatingBuy$300.00
4/15/2020Morgan StanleyBoost TargetOverweight$251.00 ➝ $258.00
3/27/2020Piper SandlerReiterated RatingBuy$300.00
3/12/2020Wolfe ResearchInitiated CoverageOutperform$282.00
3/11/2020Cantor FitzgeraldReiterated RatingOverweight$262.00 ➝ $275.00
3/4/2020BarclaysInitiated CoverageOverweight$271.00
3/3/2020CowenReiterated RatingBuy$260.00
3/2/2020ArgusBoost TargetPositive ➝ Buy$248.00 ➝ $270.00
2/2/2020Evercore ISIReiterated RatingHold$270.00
1/31/2020Piper SandlerBoost Target$284.00 ➝ $300.00
1/31/2020Bank of AmericaReiterated RatingBuy$250.00 ➝ $295.00
1/31/2020Needham & Company LLCReiterated RatingHold
1/31/2020Morgan StanleyBoost TargetOverweight$250.00 ➝ $251.00
1/31/2020Stifel NicolausBoost TargetBuy$243.00 ➝ $275.00
1/31/2020Royal Bank of CanadaBoost TargetOutperform$240.00 ➝ $260.00
1/31/2020CfraBoost TargetBuy$237.00 ➝ $286.00
1/31/2020Credit Suisse GroupBoost TargetOutperform$253.00 ➝ $258.00
1/31/2020SunTrust BanksReiterated RatingBuy$285.00
1/31/2020JPMorgan Chase & Co.Boost TargetOverweight$247.00 ➝ $260.00
1/31/2020HC WainwrightBoost TargetBuy$220.00 ➝ $270.00
1/31/2020Robert W. BairdDowngradeOutperform ➝ Neutral$210.00 ➝ $230.00
1/14/2020JPMorgan Chase & Co.Reiterated RatingBuy
1/9/2020BMO Capital MarketsBoost Target$248.00 ➝ $268.00
1/8/2020OppenheimerBoost TargetOutperform$230.00 ➝ $265.00
1/6/2020Piper Sandler CompaniesBoost TargetOverweight$247.00 ➝ $284.00
1/2/2020Raymond JamesDowngradeOutperform ➝ Market Perform
12/18/2019JPMorgan Chase & Co.Boost TargetOverweight$218.00 ➝ $247.00
12/16/2019ArgusBoost TargetBuy$248.00
12/13/2019Credit Suisse GroupUpgradeBuy$231.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

1.14 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 60 very positive mentions
  • 28 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
4/24/2024
  • 50 very positive mentions
  • 21 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
5/24/2024
  • 56 very positive mentions
  • 14 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
6/23/2024
  • 39 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
7/23/2024
  • 47 very positive mentions
  • 27 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 43 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 41 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 78 very positive mentions
  • 30 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 78 very positive mentions
  • 30 positive mentions
  • 3 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Vertex Pharmaceuticals logo
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $451.23
Low: $445.38
High: $451.76

50 Day Range

MA: $475.38
Low: $448.01
High: $516.74

52 Week Range

Now: $451.23
Low: $346.29
High: $519.88

Volume

1,642,925 shs

Average Volume

1,185,861 shs

Market Capitalization

$116.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39

Frequently Asked Questions

What sell-side analysts currently cover shares of Vertex Pharmaceuticals?

The following Wall Street analysts have issued stock ratings on Vertex Pharmaceuticals in the last twelve months: Argus, Bank of America Co., Barclays PLC, BMO Capital Markets, Canaccord Genuity Group Inc., Cantor Fitzgerald, Citigroup Inc., Evercore ISI, Guggenheim, HC Wainwright, JPMorgan Chase & Co., Maxim Group, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Redburn Atlantic, Robert W. Baird, Royal Bank of Canada, Sanford C. Bernstein, Scotiabank, Stifel Nicolaus, StockNews.com, TD Cowen, Truist Financial Co., UBS Group AG, Wells Fargo & Company, William Blair, and Wolfe Research.
View the latest analyst ratings for VRTX.

What is the current price target for Vertex Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Vertex Pharmaceuticals in the last year. Their average twelve-month price target is $499.12, suggesting a possible upside of 10.6%. HC Wainwright has the highest price target set, predicting VRTX will reach $600.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $325.00 for Vertex Pharmaceuticals in the next year.
View the latest price targets for VRTX.

What is the current consensus analyst rating for Vertex Pharmaceuticals?

Vertex Pharmaceuticals currently has 3 sell ratings, 9 hold ratings, 17 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for VRTX.

What other companies compete with Vertex Pharmaceuticals?

Other companies that are similar to Vertex Pharmaceuticals include Amgen, Gilead Sciences, Regeneron Pharmaceuticals, Allergan and Alexion Pharmaceuticals. Learn More about companies similar to Vertex Pharmaceuticals.

How do I contact Vertex Pharmaceuticals' investor relations team?

Vertex Pharmaceuticals' physical mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company's listed phone number is (617) 341-6100 and its investor relations email address is [email protected]. The official website for Vertex Pharmaceuticals is www.vrtx.com. Learn More about contacing Vertex Pharmaceuticals investor relations.